Industry
Immunethep is available to establish collaborations with other pharmaceutical companies to accelerate the development of specific products targeting both the human and animal markets.
We have established collaborations with Merck & Co. (MSD), Merck Animal Health, GSK and Vetoquinol
Please contact us at partnerships@immunethep.com
R&D
i3S
The i3S Association merges three institutes and researchers from several schools of the UPorto, thus consolidating an extensive collaboration between all institutions spanning many years.
The long-term collaboration between IBMC, INEB and IPATIMUP - the three founding institutes of i3S - encompasses joint projects, co-supervision of PhD students, sharing of large equipment and employment of research staff under coordinated policies.
Clinical Trials
IMMUNETHEP is currently looking for partner institutions (Hospitals, Clinics, and Patients Associations) to conduct Clinical Trials for the products in its pipeline. Please contact us if your institution is interested in knowing more about this opportunity.
If you wish to volunteer for a clinical trial, please send us an email: clinicaltrials@immunethep.com
Affiliations
Portugal’s Biotechnology Industry Organization (P-BIO)
Portugal’s Biotechnology Industry Organization (P-BIO) is a national association that brings together the vast majority of companies linked to the biotechnology and life sciences sector. Since it was founded in 1999, it has been the cornerstone for the development and support of biotechnology in Portugal.
P-BIO seeks to develop an environment that is favorable to the creation and growth of start-ups, promoting their corporate development domestically and internationally.
BEAM Alliance
Launched in June 2015, the BEAM Alliance (Biotech companies from Europe innovating in Anti-Microbial resistance research) represents over 60 small and medium-sized European companies involved in developing innovative products and kits to tackle antimicrobial resistance (AMR), including small molecule antibiotics, biologics, products with a prophylaxis indication, microbiome-based, and phage-based therapies, immune targeting therapies, anti-biofilm agents and medical devices including in vitro diagnostics.
Funding
Portugal 2020
Portugal 2020 was the national programme of EU funds destined to support the Portuguese economy under the framework for the period 2014-2020, in particular for R&D and innovation initiatives. Immunethep has received funds for 3 projects under this program:
- CENTRO-01-02B7-FEDER-060491
- CENTRO-01-0247-FEDER-045262
- CENTRO-01-0247-FEDER-011211
Bill and Melinda Gates Foundation
The Bill and Melinda Gates Foundation (BMGF) has supported Immunethep through an R&D grant to assess if oral delivered anti-GAPDH antibodies can prevent GBS infections.
European Innovation Council
The European Innovation Council (EIC) has selected Immunethep to receive funding from its EIC Accelerator programme. Immunethep is receiving an initial Grant and is eligible for additional Equity investment from the EIC Fund for a project that comprises a total investment of €17.5 million.
CARB-X
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, a leading cause of death around the world.
CARB-X has awarded Immunethep $2 million in funding to support the development of our conjugated peptide-based vaccine against invasive Escherichia coli infections.
PACE
Pathways to Antimicrobial Clinical Efficacy (PACE) brings together the best minds in antimicrobial resistance (AMR) research and connects them to the right funding, the right resources, and the right partnerships.
PACE has awarded Immunethep £1M in funding to advance monoclonal antibodies that restore the ability to control bacterial infection.